Article

Nemeroff CB, Bissette G, Akil H, Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 158: 59-63

Department of Psychiatry and Pharmacology, Duke University Medical Center, Durham, North Carolina 27710.
The British Journal of Psychiatry (Impact Factor: 7.34). 02/1991; 158:59-63. DOI: 10.1192/bjp.158.1.59
Source: PubMed

ABSTRACT The CSF concentrations of CRF, somatostatin and beta-endorphin were determined in nine patients who fulfilled DSM-III criteria for major depression with psychotic features. CSF samples were obtained at baseline in the depressed state, and again after a course of ECT. Concentrations of both CRF and beta-endorphin decreased after ECT, while the concentration of somatostatin increased, although the latter difference did not attain statistical significance. The increase in CSF concentrations of CRF and beta-endorphin in depressed patients is therefore seen to be state-dependent.

Download full-text

Full-text

Available from: Charles B Nemeroff, Aug 25, 2015
0 Followers
 · 
53 Views
  • Source
    • "The role of the CRF system in depression has been supported by clinical studies showing that depressed patients have higher CSF concentrations of CRF (Nemeroff et al. 1984), and depressed patients who died by suicide exhibit increased expression of CRF mRNA in the hypothalamus and PFC (Austin et al. 2003; Merali et al. 2004; Nemeroff et al. 1988; Raadsheer et al. 1994) as well as a reduction in CRF receptor binding density (Owens et al. 1991) and CRF receptor mRNA expression (Merali et al. 2004). Moreover, CSF concentrations of CRF are reduced by electroconvulsive therapy (Nemeroff et al. 1991) and antidepressant treatments (De Bellis et al. 1993; Heuser et al. 1998; Veith et al. 1993). Early relapse of depression is also associated with elevated concentrations of CSF CRF (Banki et al. 1992). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stress Stress mediates the activation of a variety of systems ranging from inflammatory to behavioral responses. In this review we focus on two neuropeptide systems, corticotropin-releasing factor corticotropin-releasing factor (CRF) and arginine vasopressin arginine vasopressin (AVP), and their roles in regulating stress stress responses. Both peptides have been demonstrated to be involved in anxiogenic and depressive effects, actions mediated in part through their regulation of the hypothalamic-pituitary-adrenal axis and the release of adrenocorticotropic hormone. Because of the depressive effects of CRF and AVP, drugs modifying the stress stress -associated detrimental actions of CRF and AVP are under development, particularly drugs antagonizing CRF and AVP receptors for therapy in depression.
    03/2014; DOI:10.1007/7854_2014_306
  • Source
    • "Chronic stress is a risk factor, and possibly a causal factor, in the development of depression and anxiety disorders (Kendler et al., 1999; Koenen et al., 2002, 2007; Gilmer et al., 2005; Jordanova et al., 2007). Indeed, a number of physiological and anatomical alterations associated with chronic stress are hallmarks of depression and anxiety disorders (Board et al., 1956; Nemeroff et al., 1984, 1991; Gold et al., 1986; Holsboer et al., 1986; Weisse, 1992; Heuser et al., 1998; Arborelius et al., 1999; Manji et al., 2001; McEwen, 2003). In addition to cumulative or chronic stress, severe acute stress is also associated with mood and anxiety disorders, most prominently with PTSD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stress is a risk factor for the development of affective disorders, including depression, post-traumatic stress disorder, and other anxiety disorders. However, not all individuals who experience either chronic stress or traumatic acute stress develop such disorders. Thus, other factors must confer a vulnerability to stress, and exposure to early-life stress may be one such factor. In this study we examined prenatal stress (PNS) as a potential vulnerability factor that may produce stable changes in central stress response systems and susceptibility to develop fear- and anxiety-like behaviors after adult stress exposure. Pregnant Sprague-Dawley rats were immobilized for 1 h daily during the last week of pregnancy. Controls were unstressed. The male offspring were then studied as adults. As adults, PNS or control rats were first tested for shock-probe defensive burying behavior, then half from each group were exposed to a combined chronic plus acute prolonged stress (CAPS) treatment, consisting of chronic intermittent cold stress (4 °C, 6 h/d, 14 days) followed on day 15 by a single session of sequential acute stressors (social defeat, immobilization, cold swim). After CAPS or control treatment, different groups were tested for open field exploration, social interaction, or cued fear conditioning and extinction. Rats were sacrificed at least 5 days after behavioral testing for measurement of tyrosine hydroxylase (TH) and glucocorticoid receptor (GR) expression in specific brain regions, and plasma adrenocorticotropic hormone (ACTH) and corticosterone. Shock-probe burying, open field exploration and social interaction were unaffected by any treatment. However, PNS elevated basal corticosterone, decreased GR protein levels in hippocampus and prefrontal cortex, and decreased TH mRNA expression in noradrenergic neurons in the dorsal pons. Further, rats exposed to PNS plus CAPS showed attenuated extinction of cue-conditioned fear. These results suggest that PNS induces vulnerability to subsequent adult stress, resulting in an enhanced fear-like behavioral profile, and dysregulation of brain noradrenergic and hypothalamic-pituitary-adrenal axis (HPA) activity.
    Neuroscience 06/2011; 192:438-51. DOI:10.1016/j.neuroscience.2011.06.041 · 3.33 Impact Factor
  • Source
    • "Reduced CRH levels in CSF were also reported after electroconvulsive therapy ( ECT ; Kling and others 1994 ; Nemeroff and others 1991 ; Nikisch and Mathe 2008 ) . Because HPA axis function was found to be normalized with the resolution of depressive psychopathology ( Holsboer and Barden 1996 ) , these reports support the hypothesis that an impaired central CRH system plays an essential role in the etiology of depression and that suc - cessful antidepressant treatment may help to correct such a dysregulation . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stress response and depression have a significant impact on modern society. Although the symptoms are well characterized, the molecular mechanisms underlying depression are largely unknown. The monoamine hypothesis, which postulates dysfunctional noradrenergic and serotonergic systems as the underlying primary cause of depression, has been valuable for the development of conventional antidepressants, which can reverse these dysfunctional states to some degree. However, recent data from various neuroscience disciplines have questioned the major role of amines in the pathogenesis of depression. A considerable amount of evidence has accumulated that suggests that normalization of the hypothalamo-pituitary-adrenal (HPA) system might be the final step necessary for a remission of depression. In addition, an increasing body of clinical and postmortem evidence is pointing to a role played by γ-aminobutyric acid (GABA) and glutamate in the etiology of depression. This review examines the evidence, mainly obtained from clinical studies or from postmortem brain material, for a major role of the HPA axis, glutamatergic, and GABAergic systems in the pathogenesis of major and bipolar depression. The authors hope that these insights will stimulate further studies with the final aim of developing new types of antidepressants that combine increased efficacy with a shorter delay of the onset of action and reduced side-effect profiles.
    The Neuroscientist 03/2010; 17(1):124-44. DOI:10.1177/1073858410361780 · 7.62 Impact Factor
Show more